CU to Study How Psilocybin Affects Mental Health of Cancer Patients

For the first time ever, the National Cancer Institute is funding a study that will look into psilocybin’s effect on the emotional and mental suffering of terminal cancer patients. Led by CU doctors Stacy Fischer and Jim Grigsby, the study will monitor patients who undergo extensive sessions of psychotherapy, during which each participant will receive 25 milligrams of psilocybin, a “moderate to high dose” that is enough for ego dissolution, according to Fischer.